KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Treasury Shares (2020 - 2026)

Castle Biosciences' Treasury Shares history spans 6 years, with the latest figure at $3.4 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 6.24% to $3.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.4 million, a 6.24% increase, with the full-year FY2025 number at $3.4 million, up 6.24% from a year prior.
  • Treasury Shares hit $3.4 million in Q4 2025 for Castle Biosciences, up from $350144.0 in the prior quarter.
  • Over the last five years, Treasury Shares for CSTL hit a ceiling of $3.5 million in Q4 2022 and a floor of $196033.0 in Q4 2023.
  • Historically, Treasury Shares has averaged $1.9 million across 5 years, with a median of $2.1 million in 2021.
  • Biggest five-year swings in Treasury Shares: plummeted 94.36% in 2023 and later skyrocketed 1530.45% in 2024.
  • Tracing CSTL's Treasury Shares over 5 years: stood at $1.1 million in 2021, then skyrocketed by 231.18% to $3.5 million in 2022, then crashed by 94.36% to $196033.0 in 2023, then skyrocketed by 1530.45% to $3.2 million in 2024, then rose by 6.24% to $3.4 million in 2025.
  • Business Quant data shows Treasury Shares for CSTL at $3.4 million in Q4 2025, $350144.0 in Q3 2025, and $3.2 million in Q4 2024.